Wound Management Technologies Completes Acquisition Of BioPharma Management Technologies

Wound Management Technologies has completed the acquisition of BioPharma Management Technologies, a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management and resorbable orthoses.

Reportedly, BioPharma is now a wholly owned subsidiary of Wound Management Technologies in exchange for 4,500,000 shares of Wound Management Technologies common stock.

Scott Haire, chief executive officer of Wound Management Technologies, said: “BioPharma’s proprietary technologies and its future products are complementary to our major product CellerateRx. BioPharma provides broad new applications across several of the medical markets that we currently serve.

“Over the past year we have made excellent progress in bringing the science and technology of CellerateRx to the market. Now with the acquisition of BioPharma, we are adding additional science and technology that strengthen Wound Management Technologies’ role as a global provider of wound care products.”

CellerateRx is a collagen hydrolysate polypeptid, which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds.